Treatment
Autologous Tumor Infiltrating Lymphocytes clinical trials
We’re tracking 17 recruiting studies that include Autologous Tumor Infiltrating Lymphocytes, each written for real people, not researchers, below.
Recruiting studies
- NCT06241781RecruitingPhase 2
Immune cells from your tumor for cervical cancer
This trial tests a new treatment using your own immune cells (called tumor-infiltrating lymphocytes) that are grown in a lab and given back to you. It is for people with cervical cancer that has come back or spread and hasn't been stopped by other treatments.
Beijing, Beijing MunicipalityAges 18–70 - NCT06397963Recruiting
Personalized immune cell therapy for advanced solid tumors
This study tests a new treatment using your body's own immune cells (called tumor-infiltrating lymphocytes) that are taken from your tumor, grown in a lab, and then put back into you. It's for people with advanced solid tumors who have run out of standard options.
Beijing, Beijing MunicipalityAges 18–70 - NCT06453057Recruiting
TIL therapy for ovarian cancer
This trial tests a new therapy made from your own immune cells (called TILs) to fight ovarian cancer. Doctors remove some of your tumor, grow the immune cells in a lab, and then give them back to you to attack the cancer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06488950RecruitingEarly Phase 1
TIL therapy for advanced solid tumors
This trial tests a new type of personalized cell therapy (TIL) for people with advanced solid tumors who have run out of standard treatment options. It aims to see if this approach can help shrink tumors.
ShanghaiAges 18–75 - NCT06598371RecruitingPhase 1/Phase 2
Study of engineered immune cells for advanced solid tumors
This trial tests a new treatment made from your own immune cells (called tumor-infiltrating lymphocytes) that are genetically modified to fight cancer better. It is for people with certain advanced solid tumors that have not responded well to other treatments.
Houston, TexasAges 18 years+ - NCT06047977RecruitingPhase 1
Immune cell therapy for high-risk solid tumors in children and young adults
This trial uses a patient's own tumor-fighting immune cells (TILs) to treat high-risk solid tumors outside the brain in children and young adults. It has two parts: first, a tumor sample is collected during surgery, and then the immune cells are grown in a lab and given back to the patient to attack the cancer.
St. Petersburg, FloridaAges 1–21 - NCT06819280Recruiting
Immune cells for advanced colorectal cancer after first treatment
This trial tests whether your own immune cells, called tumor-infiltrating lymphocytes (TILs), can be grown in a lab and given back to you to fight advanced colorectal cancer. It is for people whose cancer has continued to grow after their first round of chemotherapy.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05831033RecruitingEarly Phase 1
Your own immune T-cells to treat advanced solid tumors
This early-phase study tests a treatment made from your own tumor-fighting immune cells (TIL cells) for advanced solid cancers that have worsened or no longer respond to standard therapy. The main goal is to learn whether it is safe and whether it can shrink tumors for people who have limited options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07560111RecruitingPhase 2
GC101 cell therapy for advanced lung cancer
This study tests GC101, a new cell-based treatment for non-small cell lung cancer in patients who have already tried other targeted drugs. The trial involves surgically removing some tumor tissue to grow immune cells in the lab, then infusing them back into your body to fight the cancer.
ShanghaiAges 18–70 - NCT06473961RecruitingPhase 1
GC101 cell therapy for advanced non-small cell lung cancer
This trial tests an experimental cell therapy (GC101) for people with advanced non-small cell lung cancer. It uses your own tumor-fighting immune cells, called TILs, grown in a lab and given back to you. The goal is to see if it can shrink tumors or slow the disease.
ShanghaiAges 18–70 - NCT05366478RecruitingPhase 1
LM103 for advanced solid tumors using donated immune cells
This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.
TianjinAges 18 years+ - NCT06084299RecruitingPhase 1
Immune cell therapy for advanced liver cancer
This trial tests a new treatment using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It is for people whose cancer has progressed after at least two standard treatments and who have tumors that can be biopsied to grow these cells.
WuhanAges 18–70 - NCT06463522RecruitingPhase 1/Phase 2
Immune cell therapy for liver cancer
This trial tests using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It may help if you have Barcelona Clinic Liver Cancer (BCLC) stage B or C and your liver function is still fairly good.
BeijingAges 18–70 - NCT07651124Recruiting
Testing a cell therapy for recurrent ovarian cancer
This trial tests a treatment where doctors take immune cells from your tumor, grow more of them in the lab, and put them back into your body to fight the cancer. This approach, called TIL therapy, aims to strengthen your own immune system to target ovarian cancer that has come back.
Gyeonggi-do, Bundang-guAges 20 years+ - NCT06375187RecruitingPhase 1
GC203 TIL for advanced solid tumors
This trial tests an experimental TIL therapy (GC203) for people with advanced solid tumors who have no more standard options. Doctors will take a piece of your tumor, make it into a personalized cell treatment, and give it back to try to fight the cancer.
ShanghaiAges 18–75 - NCT06364423RecruitingPhase 1/Phase 2
CAR T-cell therapy for CD19-positive leukemias and lymphomas
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
Bethesda, MarylandAges 18–120 - NCT07109323RecruitingPhase 1/Phase 2
Stem cell transplant plus CAR-T for aggressive myeloma
This trial tests combining a stem cell transplant with a special immune cell therapy (BCMA CAR-T) to treat very aggressive multiple myeloma. The goal is to see if this powerful one-two punch can help people whose myeloma is hard to control.
Tianjin, Tianjin MunicipalityAges 18–70
What Autologous Tumor Infiltrating Lymphocytes is being studied for
Conditions with recruiting Autologous Tumor Infiltrating Lymphocytes studies.
Common questions
- Are there clinical trials studying Autologous Tumor Infiltrating Lymphocytes?
- Yes. Clin2 currently lists 17 recruiting studies that include Autologous Tumor Infiltrating Lymphocytes, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Autologous Tumor Infiltrating Lymphocytes trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Autologous Tumor Infiltrating Lymphocytes an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Autologous Tumor Infiltrating Lymphocytes or a specific trial is right for you.
Related treatments
- Tumor Infiltrating Lymphocytes
- Tumor Infiltrating Lymphocyte
- Personalized neoantigen tumor vaccine
- Tumor-draining lymph node-derived lymphocyte
- individualized anti-tumor new antigen iNeo-Vac-R01
- Anti-CD19-CAR CMV-specific T-lymphocytes
- Renal Autologous Cell Therapy
- Β-globin Restored Autologous Hematopoietic Stem Cells
- Pembrolizumab
- Cyclophosphamide
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.